ArticleBMC cancer2021

A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.

Alexander Grunenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.